In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

The approval includes patients whose disease progressed after treatment with endocrine therapy, which can cause ESR1 mutations.

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

Patients on Enhertu and Perjeta lived more than three years without disease progression compared to just over two years on Perjeta, Herceptin, and chemo.

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.

The firm has licensed Solid's AAV-SLB101 capsid and plans to fund preclinical development with a potential $1.1 million investment from the Jain Foundation.

Recent studies are revealing how genetic counselors are adapting their practice amid state laws banning or restricting abortions.

The company submitted data showing A400's efficacy in patients with advanced RET fusion-positive NSCLC in first- or later-line treatment.

The firm's lead candidate, EN-374 for X-linked chronic granulomatous disease, is being evaluated in a Phase I/II trial.

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...